Stefania Kalampokini

Dr. Stefania Kalampokini

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Closed access
PDF file
SKStefania Kalampokini
Stefania Kalampokini
AHAdrianus L. A. J. Hommel
Adrianus L. A. J. Hommel
SLStefan Lorenzl
Stefan Lorenzl
JFJoaquim J. Ferreira
Joaquim J. Ferreira
WMWassilios G. Meissner
Wassilios G. Meissner
ASAnette-Eleonore Schrag
Anette-Eleonore Schrag
Patients in the late stages of parkinsonism are highly dependent on others in their self-care and activities of daily living. However, few studies have assessed the physical, psychological and social consequences of caring for a person with late-stage parkinsonism. Five hundred and six patients and their caregivers from the Care of Late Stage Parkinsonism (CLaSP) study were included. Patients’ motor and non-motor symptoms were assessed using the UPDRS and Non-motor symptom scale (NMSS), Neuropsychiatric inventory (NPI-12), and caregivers’ health status using the EQ-5D-3 L. Caregiver burden was assessed by the Zarit Burden Interview (ZBI). The majority of caregivers were the spouse or life partner (71.2%), and were living with the patient at home (67%). Approximately half of caregivers reported anxiety/depression and pain/discomfort (45% and 59% respectively). The factors most strongly associated with caregiver burden were patients’ neuropsychiatric features on the total NPI score (r = 0.38, p < 0.0001), total NMSS score (r = 0.28, p < 0.0001), caring for male patients and patients living at home. Being the spouse, the hours per day assisting and supervising the patient as well as caregivers’ EQ-5D mood and pain scores were also associated with higher ZBI scores (all p < 0.001). The care of patients with late stage parkinsonism is associated with significant caregiver burden, particularly when patients manifest many neuropsychiatric and non-motor features and when caring for a male patient at home.

1 September 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
SKStefania Kalampokini
Stefania Kalampokini
AAArtemios Artemiadis
Artemios Artemiadis
PZPanagiotis Zis
Panagiotis Zis
LHLinos Hadjihannas
Linos Hadjihannas
GPGeorgios Mamas Parpas
Georgios Mamas Parpas
GHGeorgios M. Hadjigeorgiou
Georgios M. Hadjigeorgiou

22 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Panagiotis ZisPanagiotis Zis
Panagiotis Zis
CIChristiana Ioannou
Christiana Ioannou
Artemios ArtemiadisArtemios Artemiadis
Artemios Artemiadis
KCKaterina Christodoulou
Katerina Christodoulou
SKStefania Kalampokini
Stefania Kalampokini
GHGeorgios Hadjigeorgiou
Georgios Hadjigeorgiou
Introduction: Chronic pain is increasingly recognized as part of long COVID syndrome, mainly in the form of myalgias. However, chronic pain has several forms, and according to our clinical experience, COVID-19 survivors suffer from numerous painful syndromes, other than myalgias. The aim of our study was to estimate the prevalence of chronic pain, describe the commonest painful syndromes and identify pain determinants in a random population of COVID-19 survivors. Methods: This was a cross-sectional study conducted at the Medical School, University of Cyprus. A random population of 90 COVID-19 survivors was recruited. Demographic and COVID-19 related clinical characteristics were recorded. The painDETECT and DN4 questionnaires were used to evaluate the painful syndromes. Results: The prevalence of chronic pain was estimated to be 63.3%. The most common site of pain was low back (37.8%), followed by joints (28.9%) and neck (12.2%). Patients with chronic pain compared to subjects without pain were older (50.5 ± 15.9 versus 42.2 ± 12.6, p = 0.011) and more likely to be female (71.9% versus 45.5%, p = 0.013). One in six subjects (16.7%) reported new-onset pain post COVID-19. The prevalence of neuropathic pain was estimated to be 24.4%. After adjusting for age and gender, headache during COVID-19 was a statistically significant predictor of neuropathic pain, increasing 4.9 times (95% 1.4–16.6, p = 0.011) the odds of neuropathic pain. Conclusion: Chronic pain—especially neuropathic—is widely prevalent in COVID-19 survivors. One in six subjects will develop new-onset pain that will persist beyond the acute phase of the disease and, therefore, should be considered a symptom of long COVID syndrome.

1 March 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
SKStefania Kalampokini
Stefania Kalampokini
DGDespoina Georgouli
Despoina Georgouli
KDKaterina Dadouli
Katerina Dadouli
PNPanagiotis Ntellas
Panagiotis Ntellas
SRStella Ralli
Stella Ralli
GXGeorgia Xiromerisiou
Georgia Xiromerisiou

25 August 2019 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SKStefania Kalampokini
Stefania Kalampokini
ABAnouck Becker
Anouck Becker
KFKlaus Fassbender
Klaus Fassbender
ELEpameinondas Lyros
Epameinondas Lyros
MUMarcus M. Unger
Marcus M. Unger
Neuroinflammation is increasingly recognized as an important pathophysiological feature of neurodegenerative diseases such as Parkinson’s disease (PD). Recent evidence suggests that neuroinflammation in PD might originate in the intestine and the bidirectional communication between the central and enteric nervous system, the so-called “gut-brain axis,” has received growing attention due to its contribution to the pathogenesis of neurological disorders. Diet targets mediators of inflammation with various mechanisms and combined with dopaminergic treatment can exert various beneficial effects in PD. Food-based therapies may favorably modulate gut microbiota composition and enhance the intestinal epithelial integrity or decrease the proinflammatory response by direct effects on immune cells. Diets rich in pre- and probiotics, polyunsaturated fatty acids, phenols including flavonoids, and vitamins, such as the Mediterranean diet or a plant-based diet, may attenuate chronic inflammation and positively influence PD symptoms and even progression of the disease. Dietary strategies should be encouraged in the context of a healthy lifestyle with physical activity, which also has neuroimmune-modifying properties. Thus, diet adaptation appears to be an effective additive, nonpharmacological therapeutic strategy that can attenuate the chronic inflammation implicated in PD, potentially slow down degeneration, and thereby modify the course of the disease. PD patients should be highly encouraged to adopt corresponding lifestyle modifications, in order to improve not only PD symptoms, but also general quality of life. Future research should focus on planning larger clinical trials with dietary interventions in PD in order to obtain hard evidence for the hypothesized beneficial effects.

21 June 2017 in Journal of Clinical and Experimental Neuropsychology
Verified
Journal Article
Closed access
SKStefania Kalampokini
Stefania Kalampokini
ELE. Lyros
E. Lyros
MLM. Luley
M. Luley
JSJ. Schöpe
J. Schöpe
JSJ. Spiegel
J. Spiegel
MUM. M Unger
M. M Unger
Objective: The ability to recognize facial emotion expressions has been reported to be impaired in Parkinson’s disease (PD), yet previous studies showed inconsistent findings. The aim of this study was to further investigate facial emotion recognition (FER) in PD patients and its association with demographic and clinical parameters (including motor and nonmotor symptoms). Method: Thirty-four nondemented PD patients and 24 age- and sex-matched healthy controls (HC) underwent clinical neurological and neuropsychological assessment, standardized olfactory testing with Sniffin’ Sticks, and the Ekman 60 Faces Emotion Recognition Test. Results: PD patients had a significantly lower score on the total FER task than HC (p = .006), even after controlling for the potential confounding factors depression and apathy. The PD group had a specific impairment in the recognition of surprise (p = .007). The recognition of anger approached statistical significance (p = .07). Increasing chronological age and age at disease onset were associated with worse performance on the FER task in PD patients. Olfactory function along with PD diagnosis predicted worse FER performance within all study participants. Conclusion: Facial emotion recognition and especially the recognition of surprise are significantly impaired in PD patients compared with age- and sex-matched HC. The association of FER with age and olfactory function is endorsed by common structures that undergo neurodegeneration in PD. The relevance of FER in social interaction stresses the clinical relevance and the need for further investigation in this field. Future studies should also determine whether impaired FER is already present in premotor stages of PD.